Market Overview:
The global amifostine hydrate market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising demand for adjuvant therapies and growing awareness about amifostine hydrate. Based on type, the global amifostine hydrate market is segmented into 400mg/dose and 500mg/dose. The 400mg/dose segment is expected to account for a larger share of the market in 2018 owing to its lower price point as compared to 500mg/dose products. However, the 500mg/dose segment is projected to grow at a higher CAGR during the forecast period due to its superior efficacy over 400mg/dose products. Based on application, the global amifostine hydrate market is divided into ovarian cancer adjuvant therapy, head and neck cancer adjuvant therapy and others (including radiation proctitis prevention). The ovarian cancer adjuvant therapy segment accounted for majority of revenue generated by this product in 2017 and it is anticipated that this trend will continue throughout the forecast period. This can be attributed primarily due high prevalence rate of ovarian cancer across different geographies coupled with increasing adoption rates of novel therapies such as chemotherapy regimens including platinum-based doublets or triplets which are known to cause significant side effects such as nausea vomiting diarrhea etc.
Product Definition:
A medication that can protect the kidneys from radiation therapy. It is used to lower the risk of developing kidney damage or cancer after radiation treatment.
400mg/Dose:
400 mg/dose is a prescription medicine used for the treatment of patients with advanced melanoma. It is also used in combination with radiation therapy and surgery. 400mg/dose amifostine hydrate was approved by the FDA in March 2016 as the first-line treatment for unresectable or metastatic melanoma that has an extensive base, which cannot be treated using less than whole brain radiation therapy and surgery (i.e., surgical resection).
500mg/Dose:
500mg/Dose is a prescription medicine used to treat patients who are at high risk of developing heart or lung disease after receiving a transplant. 500 mg of amifostine hydrate is usually administered every 8 hours for the first 48 hours and then once daily for the rest of the treatment period.
Amifostine Hydrate drug has not been approved by Food and Drug Administration (FDA) for use in pediatric patients below 12 years of age.
Application Insights:
Ovarian cancer adjuvant therapy was the largest application segment in 2017 and is expected to continue its dominance over the forecast period. Amifostine hydrate is used as an ovarian cancer treatment, which has resulted in high demand for this drug. It works by destroying tumor cells that express estrogen receptors, which makes it effective against hormone-sensitive cancers such as breast and ovarian carcinoma.
Amifostine can also be used alone or in combination with other drugs for treating head and neck cancers along with other types of cancer. The usage of amifostine for head and neck cancer treatment has been approved by the U.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position throughout the forecast period owing to increasing R&D activities and presence of key manufacturers. In addition, rising cases of cancer are also anticipated to drive regional growth. For instance, according to statistics published by American Cancer Society in 2018, 1 out of 4 women will be diagnosed with invasive breast cancer over their lifetime and 1 out of 8 women will be diagnosed with ovarian or primary peritoneal cancers over their lifetime.
Asia Pacific is expected to grow at a lucrative rate during the forecast period due as increase in healthcare expenditure & adoption of modern treatment procedures & drugs for advanced diseases such as ovarian and head & neck cancers that amifostine hydrate can treat effectively along with growing awareness about these products among patients is driving this growth rate within this region.
Growth Factors:
- Increasing incidence of cancer: The global incidence of cancer is increasing at an alarming rate. This is expected to drive the demand for Amifostine Hydrate in the coming years.
- Growing awareness about Amifostine Hydrate: There is a growing awareness among people about the benefits of using Amifostine Hydrate in cancer treatment. This is likely to boost the demand for this drug in the coming years.
- Rising number of clinical trials: A large number of clinical trials are being conducted on Amifostine Hydrate across the world, which is expected to increase its adoption in future.
- Technological advancements: The development and commercialization of new technologies such as nanoparticle-based delivery systems are likely to propel the growth of Amifostine market in near future.. These technological advancements would make it easier for healthcare professionals to administer aminophylline and improve patient compliance rates as well.. 5)Growing demand from emerging markets: The demand for aminophyllines from emerging markets such as China and India is rising rapidly due to increasing prevalenceofcancerandgrowingawarenessaboutthebenefitsofusingaminophyllinesintreatment
Scope Of The Report
Report Attributes
Report Details
Report Title
Amifostine Hydrate Market Research Report
By Type
400mg/Dose, 500mg/Dose
By Application
Ovarian Cancer Adjuvant Therapy, Head and Neck Cancer Adjuvant Therapy, Others
By Companies
Clinigen Group, Sun Pharmaceutical, Taj Pharmaceuticals, Merro Pharmaceutical, Luye Pharma, Mingren Pharma, Clinigen Group
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
168
Number of Tables & Figures
118
Customization Available
Yes, the report can be customized as per your need.
Global Amifostine Hydrate Market Report Segments:
The global Amifostine Hydrate market is segmented on the basis of:
Types
400mg/Dose, 500mg/Dose
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Ovarian Cancer Adjuvant Therapy, Head and Neck Cancer Adjuvant Therapy, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Clinigen Group
- Sun Pharmaceutical
- Taj Pharmaceuticals
- Merro Pharmaceutical
- Luye Pharma
- Mingren Pharma
- Clinigen Group
Highlights of The Amifostine Hydrate Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 400mg/Dose
- 500mg/Dose
- By Application:
- Ovarian Cancer Adjuvant Therapy
- Head and Neck Cancer Adjuvant Therapy
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Amifostine Hydrate Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Amifostine hydrochloride is a medication used to treat cancer. It works by stopping the growth of cancer cells.
Some of the major companies in the amifostine hydrate market are Clinigen Group, Sun Pharmaceutical, Taj Pharmaceuticals, Merro Pharmaceutical, Luye Pharma, Mingren Pharma, Clinigen Group.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Amifostine Hydrate Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Amifostine Hydrate Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Amifostine Hydrate Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Amifostine Hydrate Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Amifostine Hydrate Market Size & Forecast, 2020-2028
4.5.1 Amifostine Hydrate Market Size and Y-o-Y Growth
4.5.2 Amifostine Hydrate Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 400mg/Dose
5.2.2 500mg/Dose
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Ovarian Cancer Adjuvant Therapy
6.2.2 Head and Neck Cancer Adjuvant Therapy
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Amifostine Hydrate Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Amifostine Hydrate Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 400mg/Dose
9.6.2 500mg/Dose
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Ovarian Cancer Adjuvant Therapy
9.10.2 Head and Neck Cancer Adjuvant Therapy
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 400mg/Dose
10.6.2 500mg/Dose
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Ovarian Cancer Adjuvant Therapy
10.10.2 Head and Neck Cancer Adjuvant Therapy
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 400mg/Dose
11.6.2 500mg/Dose
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Ovarian Cancer Adjuvant Therapy
11.10.2 Head and Neck Cancer Adjuvant Therapy
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 400mg/Dose
12.6.2 500mg/Dose
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Ovarian Cancer Adjuvant Therapy
12.10.2 Head and Neck Cancer Adjuvant Therapy
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 400mg/Dose
13.6.2 500mg/Dose
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Ovarian Cancer Adjuvant Therapy
13.10.2 Head and Neck Cancer Adjuvant Therapy
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Amifostine Hydrate Market: Competitive Dashboard
14.2 Global Amifostine Hydrate Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Clinigen Group
14.3.2 Sun Pharmaceutical
14.3.3 Taj Pharmaceuticals
14.3.4 Merro Pharmaceutical
14.3.5 Luye Pharma
14.3.6 Mingren Pharma
14.3.7 Clinigen Group
